Company Encyclopedia
View More
name
GLORIA PHARMA.
002437.SZ
HARBIN GLORIA PHARMACEUTICALS Co., LTD engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China. Its products include cardiovascular and cerebrovascular, musculoskeletal, vitamins, electrolyte, diabetes-lowering, analgesics, digestive system and metabolism, anti-infective, and anti-tumor drugs. Harbin Gloria Pharmaceuticals Co., Ltd was founded in 2000 and is based in Harbin, the People’s Republic of China.
3.159 T
002437.SZMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
PharmaceuticalsIndustry
Industry Ranking45/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE14.47%A
    • Profit Margin13.03%B
    • Gross Margin44.88%B
  • Growth ScoreC
    • Revenue YoY-7.54%D
    • Net Profit YoY265.40%A
    • Total Assets YoY7.18%B
    • Net Assets YoY13.75%B
  • Cash ScoreC
    • Cash Flow Margin767.22%B
    • OCF YoY-7.54%D
  • Operating ScoreB
    • Turnover0.77B
  • Debt ScoreB
    • Gearing Ratio28.13%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Midday announcement: GLORIA PHARMA plans to sign an agreement to resolve the debt dispute related to the equity transfer of GLORIA BIO

    GLORIA PHARMA plans to resolve the equity transfer debt dispute with Qingdao Pusheng Puli by signing an agreement, involving a transfer payment of 117.6 million yuan for a 42.12% equity stake in Guangzhou GLORIA. Pusheng Puli has failed to make timely payments and has been sued in court. Pusheng Puli will transfer its 20.64% equity stake to Youpeng Biotechnology to repay the debt. In addition, New Times' "New Times Convertible Bonds" will stop conversion on November 4, and unconverted bonds will be forcibly redeemed, which may result in losses for investors

    Zhitong·
    SZ
    002437
    +0.62%
    Zhitong·
    SZ
    002437
    +0.62%

    GLORIA PHARMA: Puxing Puli plans to transfer 20.64% equity of GLORIA PHARMA to repay the debts owed by Puxing Puli to the company

    GLORIA PHARMA announced that it will resolve the debt dispute regarding the equity transfer payment with Pusheng Puli through an agreement. Pusheng Puli intends to transfer its 20.64% equity stake in GLORIA PHARMA to Youpeng Bio, and the proceeds will be used to repay debts owed to the company. The lawsuit regarding this equity transfer has entered the enforcement stage, and the subsequent process is complex and uncertain

    Zhitong·
    SZ
    002437
    +0.62%
    Zhitong·
    SZ
    002437
    +0.62%

    GLORIA PHARMA: Provides guarantees for 40 million bank credit for two wholly-owned subsidiaries

    GLORIA PHARMA provides a bank credit guarantee of 40 million yuan for its wholly-owned subsidiaries, Guangzhou Yudong Health Pharmaceutical Co., Ltd. and Harbin Leibotong Pharmaceutical Co., Ltd. This guarantee includes a credit of 30 million yuan for Yudong Pharmaceutical and 10 million yuan for Leibotong, with the total guarantee amount accounting for 2.06% of the audited net assets attributable to shareholders of the listed company for 2024. As of June 30, 2025, the assets and net assets of Yudong Pharmaceutical and Leibotong were 354.2715 million yuan, 306.2614 million yuan and 102.2375 million yuan, 39.9349 million yuan, respectively, with no overdue guarantee risk

    Zhitong·
    SZ
    002437
    +0.62%
    Zhitong·
    SZ
    002437
    +0.62%

    GLORIA PHARMA: Net profit in the first half of 2025 increased by 7.56% year-on-year

    GLORIA PHARMA announced that in the first half of 2025, the company achieved operating revenue of 1.1 billion yuan, a year-on-year decrease of 9.97%; the net profit attributable to shareholders of the listed company was 134 million yuan, a year-on-year increase of 7.56%; basic earnings per share were 0.0613 yuan/share, a year-on-year increase of 10.25%

    Zhitong·
    SZ
    002437
    +0.62%
    Zhitong·
    SZ
    002437
    +0.62%

    GLORIA PHARMA: Injectable multiple vitamins pass consistency evaluation

    GLORIA PHARMA announced that its wholly-owned subsidiary, Pude Pharmaceutical, has received the Drug Supplement Application Approval Notice issued by the National Medical Products Administration for injectable multivitamins. This drug has passed the consistency evaluation of the quality and efficacy of generic drugs. Injectable multivitamins are suitable for adult patients and children over 11 years old, with sales expected to reach RMB 1.916 billion in urban public hospitals and county-level public medical institutions in China in 2024. Pude Pharmaceutical has invested approximately RMB 3.6706 million in the consistency evaluation work for this drug

    Zhitong·
    SZ
    002437
    +0.62%
    Zhitong·
    SZ
    002437
    +0.62%
    © 2025 Longbridge｜Disclaimer